Colorectal Cancer

Patients with previously treated metastatic HER2-positive colorectal cancer experienced clinically meaningful and durable responses to treatment with tucatinib plus trastuzumab, according to data from the phase 2 MOUNTAINEER trial.

The combination of botensilimab and balstilimab elicited deep objective responses with evidence of durability and encouraging tolerability in heavily pretreated patients with microsatellite stable, metastatic colorectal cancer.

A second-line combination regimen comprised of RGX-202-01, FOLFIRI and bevacizumab demonstrated an encouraging efficacy signal and a favorable toxicity profile in patients with KRAS-mutant colorectal cancer.

Investigators from Rutgers Cancer Institute of New Jersey, New Jersey’s only National Cancer Institute-Designated Comprehensive Cancer Center, led a collaborative study to examine the patterns of druggable oncogenic fusions in colon cancer specimens including microsatellite-stable and unstable tumors.

Jaclyn Hechtman, MD, provides an overview of the history of molecular testing in colorectal cancer and how testing has evolved.

The EGFR inhibitor panitumumab plus a stronger chemotherapy regimen did not demonstrate a significant response benefit over an active chemotherapy comparator plus panitumumab in patients with metastatic colorectal cancer with unmutated RAS and BRAF.

Single-agent dostarlimab-gxly elicited a clinical complete response rate of 100% with no evidence of residual tumor among 14 patients with stage II/III mismatch repair–deficient locally advanced rectal cancer.

FOLFOXIRI plus bevacizumab led to a significant improvement in progression-free survival, objective response rate, and R0/1 resections vs FOLFOX/FOLFIRI plus bevacizumab but resulted in increased toxicity in patients with initially unresectable colorectal cancer liver metastases and right-sided and/or RAS- or BRAF V600E–mutated primary tumors.

Treatment with larotrectinib elicited robust and durable responses, had a favorable safety profile, and sustained survival benefit in patients with central nervous system TRK fusion cancers.

The addition of panitumumab to mFOLFOX6 improved outcomes for patients with left-sided RAS wild-type metastatic colorectal cancer compared with bevacizumab and chemotherapy in the front-line setting, according to results from the phase 3 PARADIGM trial.

Guided approaches leveraging circulating tumor DNA status can reduce the number of patients who receive adjuvant chemotherapy without the risk of lowering recurrence-free survival rates for some patients with stage II colon cancer.

Mike Cusnir, MD, discusses the utilization of SIR-Spheres® Y-90 resin microspheres as maintenance therapy in colorectal cancer.

Mike Cusnir, MD, discusses the role of Y-90 maintenance therapy in colorectal cancer and how it can supplement chemotherapy to prolong life and reduce adverse effects.

The safety and efficacy of encorafenib plus cetuximab with or without standard-of-care chemotherapy will be compared with that of chemotherapy alone in patients with BRAF V600E–mutated metastatic colorectal cancer as part of the phase 3 BREAKWATER trial.

Julia Liu, MD, discusses enrolling diverse patients in the PREEMPT CRC trial in colorectal cancer.

Aasma Shaukat, MD, MPH, discusses the methods utilized in the PREEMPT CRC trial in colorectal cancer.

The combination of tucatinib and trastuzumab produced promising response rates in patients with previously treated HER2-positive metastatic colorectal cancer.

Denalee O'Malley, PhD, sheds light on racial and ethnic disparities in colorectal cancer screening, and strategies that can be used to address existing barriers in the clinic and beyond.

Paul E. Oberstein, MD, discusses remaining challenges in metastatic colorectal cancer.

Paul E. Oberstein, MD, discusses the phase 2/3 CheckMate 9X8 trial in metastatic colorectal cancer.

Denalee O'Malley, PhD, discusses racial and economic barriers to colorectal screening in colorectal cancer.

Following in the footsteps of the cytokine interleukin-2, IL-15 affords investigators similar qualities as a target without the associated toxicities of its immunotherapeutic predecessor.

Dr Cusnir reviews the benefits of isolating the liver in early colorectal cancer (CRC) treatment, how patients have tolerated Y-90 therapy, and situations in which Y-90 therapy would be most effective for patients with CRC.

The European Commission has granted an approval to pembrolizumab for the treatment of patients with select microsatellite instability–high or deficient mismatch repair solid tumors.

Afsaneh Barzi, MD, PhD, discusses the combination of regorafenib and pembrolizumab in patients with microsatellite stable colorectal cancer.